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Abstract
Background: A previous study showed that dopamine (DA), which is contained in follicular fluid (FF) from IVF
patients, strongly increased the production of reactive oxygen species (ROS) by cultured human granulosa cells
(GCs). ROS, including H2O2, are assumed to play roles in ovarian physiology and pathology. Ovarian DA could be
derived from the circulation, ovarian innervation and/or unknown ovarian sources. L-DOPA is the direct precursor of
DA in its synthetic pathway. It was not yet described in FF. We examined L-DOPA levels in FF from IVF patients. As
it may exert anti-oxidative and ROS-scavenging functions, we studied whether it exerts such actions in human GCs
and whether DOPA-decarboxylase (DDC), the enzyme converting L-DOPA to DA, is expressed in the human ovary.
Results: ELISA measurements revealed that human IVF-derived FF contains L-DOPA. In cultured human GCs
automated confluence analyses showed that L-DOPA enhanced their survival. This is in contrast to the actions of
DA, which reduced cell survival. A dose-dependent mode of action of L-DOPA was identified using a fluorescent
ROS indicator. The results showed that it antagonized intracellular ROS accumulation induced by exogenous H2O2.
DDC was absent in follicular GCs, but immunohistochemistry identified it in theca cells (TCs) of large follicles in the
human ovary. Laser micro-dissection followed by RT-PCR corroborated the expression. DDC was also identified in
the steroidogenic cells of the corpus luteum.
Conclusions: L-DOPA in FF is an antioxidant factor and exerts positive influences on GCs. Ovarian DA is derived
from L-DOPA and has opposite actions. Exogenous L-DOPA is a standard therapy for Parkinson’s disease, and the
results raise the possibility that it may be able to exert positive actions as an antioxidant in ovarian conditions, as
well.
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Background
Reactive oxygen species (ROS) are generated in the
ovary and are assumed to play roles in ovarian physiology
as signaling molecules. They are however also involved in
ovarian pathology and act as toxic factors [1, 2].
Previous studies identified the neurotransmitters nor-
epinephrine (NE) and dopamine (DA) in the human
ovary [3]. Two studies in cultured human in vitro
fertilization (IVF)-derived granulosa cells (GCs) showed
that NE and DA stimulated the generation of ROS [4, 5]
and that the mechanisms involved intracellular uptake
and cellular metabolism of the monoamines. The intra-
cellular metabolic breakdown of monoamines generates
aldehydes and hydrogen peroxide (H2O2), which is an
important member of the class of ROS.
Monoamine-induced ROS generation is among others
linked to the levels of these factors [4, 5] and thus higher
levels of DA, for example, resulted in higher ROS levels.
Both monoamines were detected in follicular fluid (FF),
derived from IVF patients, in substantial levels. When
samples from women suffering from PCOS were com-
pared with samples from women without PCOS, a
higher concentration of DA was apparent [4]. While NE
is presumably mainly derived from the circulation and
sympathetic fibers innervating the wall of follicles, the
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reason for the high concentrations of DA in the human
ovary and specifically in PCOS patients remains un-
known. It raises the question of local production in the
ovary. DA is synthesized in several steps starting with
the ubiquitously available amino acid L-tyrosine. Previ-
ous studies failed to reveal the presence of the rate-
limiting enzyme tyrosine-hydroxylase (TH) other than in
ovarian nerves [6, 7]. Thus a substantial de novo synthe-
sis in the ovary is unlikely.
DA can be generated from L-DOPA by dopamine de-
carboxylase (DDC), an enzyme expressed in many cells
of the body. Generation of DA from exogenous L-DOPA
is the basis for the standard treatment of Parkinson's
disease patients [8–10]. Interestingly, DA likely contrib-
utes to neuronal cell death in Parkinson's disease by its
ability to increase ROS [11]. In contrast, its precursor L-
DOPA has antagonist actions and lowers ROS in neur-
onal cells [12]. The mechanisms of actions are not fully
explored, but they include induction of cellular response,
as detailed in recent studies [12, 13]. These include
changes in metabolic routes, cytoskeletal integrity,
pCREB and CD39 expression, to name a few. In
addition, ROS scavenging abilities of L-DOPA have been
established, as well [14].
The presence of high amounts of DA in FF and the
lack of knowledge about L-DOPA in FF prompted us to
explore these points. We examined human FF, GCs and
ovarian sections.
Methods
Human GC isolation, culture and treatment
As described previously, human GCs were derived from
FF aspirates of IVF patients stimulated according to rou-
tine protocols, in general the “long” stimulation protocol
was used [4, 5, 15–18]. The patients underwent IVF
treatment primarily for male factor infertility. Age varied
and ranged up to 39 years. In addition, from some of the
IVF-patients blood samples were drawn and serum was
kept at −20 °C for later analyses. FF aspirates from two
to five patients were pooled for GCs preparation, follow-
ing a method previously described [19]. It involves a cell
strainer (40 μm; BD, Franklin Lakes, NJ, USA) for filtra-
tion of the aspirates. GCs, which remained in cell
strainer, were retrieved by washing with Dulbecco’s
modified Eagle’s medium (DMEM)/Ham’s F12 Medium
(Gibco – Life Technologies, Carlsbad, CA, USA). The
filtrate was centrifuged and the supernatant (i.e., cell-
free FF) was frozen at −20 °C until further use.
Remaining cell aggregates in the acquired cell suspen-
sion were suspended mechanically by using a 0.9-mm
cannula. Washed cells were re-suspended and cultured
in DMEM/Ham’s F12 medium supplemented with peni-
cillin (100 U/ml), streptomycin (100 μg/ml) and 10 %
FCS (all from PAA) [15–18]. Primary GCs were cultured
for up to 6 days. Cells were rinsed on day 1 of culture
with fresh medium to remove non-adherent and dead
cells. For all experiments, DMEM/Ham’s F12 medium
without supplements was used. DA (Sigma-Aldrich, St
Louis, MO, USA) and L-DOPA (Sigma-Aldrich) were
used in several experiments.
Confluence measurement
GCs were cultured up to 4 days and confluence of GCs
was monitored for 24 h by taking time-lapse pictures
every 10 min using a live cell analyzer (Peqlab, Erlangen,
Germany). For each stimulation protocol (DA 200 nM,
L-DOPA 200 nM), respective control cells were ob-
served simultaneously. The software of the live cell
analyzer determined confluence values.
ELISA measurements of L-DOPA
L-DOPA was determined in FF and serum using an
enzyme-linked immunosorbent assay (ELISA) kit
(Bioassay Technology Laboratory, Shanghai, China),
following the instructions of the manufacturer. Ac-
cording to this information, the assay was validated
for human serum, body fluids, tissue and cell culture
media. Measurements were performed in microtiter
plates, and reactions were monitored at 450 nm in a
microplate reader (BMG labtech, Ortenberg, Germany).
L-DOPA in the range of 5–3200 pg/ml can be detected




DA) method was used, as described [4, 5]. In the pres-
ence of intracellular ROS, such as H2O2, the DCFH2-DA
dye (Invitrogen, Karlsruhe, Germany), after intracellular
ester hydrolysis, is converted to the highly fluorescent
compound 2-,7-dichlorofluorescein (DCF). For quantifi-
cation of ROS, GCs were placed in 96-well plates
(Thermo Fisher Scientific, Waltham, MA, USA) and
loaded with DCFH2-DA (10 mM) for 30 min at 37 °C in
DMEM/Ham’s F12 medium without phenol red (Gibco -
Life Technologies). Fluorescence levels were measured at
485 nm excitation/520 nm emission in a microplate
reader (BMG labtech) during stimulation with L-DOPA
(200 nM) and H2O2 (1 mM). After 2 h, when the experi-
ments were terminated, the final values were statistically
analyzed.
Measurement of H2O2 generation
H2O2 was measured by using an Amplex Red kit
(Invitrogen - Life Technologies, Carlsbad, CA, USA) fol-
lowing the instructions of the manufacturer. Amplex
Red was used in a final concentration of 2.5 μM. GCs
were placed in 96-well plates and fluorescence levels
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were measured for 2 h at 544 nm excitation/590 nm
emission in a microplate reader (BMG labtech). The
blank for each value was subtracted.
Immunohistochemistry
Sections of human ovaries derived from a local collec-
tion at Anatomy III, Cell Biology (Munich, Germany)
were used for immunohistochemistry. Immunohisto-
chemistry was performed with a rabbit antiserum raised
against human DDC (Sigma-Aldrich) and the corre-
sponding blocking peptide (Sigma-Aldrich). Tissue
samples and immunohistochemistry were described
previously [5, 18]. In brief, after removal of paraffin,
antigen retrieval and blocking of endogenous peroxid-
ase activity, the tissue was incubated in 5 % appropri-
ate serum, diluted in phosphate-buffered saline.
Antiserum incubation was done overnight at 4 °C.
The antiserum against human DDC was diluted 1:50.
Afterwards, incubation with a biotinylated secondary
antibody (1:500 dilution; Dianova, Hamburg, Germany)
for 2 h at room temperature was performed. A Vectastain
ABC Kit (Vector Laboratories, Burlingame, CA, USA) and
a 3,3′-diaminobenzidine tablet set (Sigma-Aldrich) were
used for the final staining procedure. Slides were covered
with Entellan (Merck Millipore, Billerica, MA, USA). For
control purposes, incubation with antigen peptide pre-
adsorbed antiserum was employed.
Laser microdissection
Human ovarian tissue samples embedded in paraffin
were cut into sections and mounted on a polyethylene
naphthalene membrane, as previously described [20].
For dissection of the cellular compartments a laser
microdissection (LMD) device (P.A.L.M. Microlaser
Technologies, Bernried, Germany) was used. RNA isola-
tion was performed by using a RNeasy Mini Kit (Qiagen,
Hilden, Germany).
Reverse transcription-PCR
Total RNA of cultured cells was isolated using the
RNeasy Mini Kit (Qiagen, Hilden, Germany). Reverse
transcription was performed with 400 ng RNA using
random hexamer primers and Superscript II (Life
Technologies). Human liver cDNA (Clontech, Mountain
View, CA, USA) was used as positive control. RT-PCR
(semi-nested) was arranged with different oligomer
primers (DDC forward: 5 -GCCCCTACTTCTTCGCC
TAC-3; DDC forward nested: 5 -ATGCTTGCGGA
CATGCTGTG-3; DDC reverse: 5 -CAGTCTCCA
GCTCTGTGCAT-3). PCR products were analyzed by
using agarose gel electrophoresis with Midori Green
(Nippon Genetics Europe GmbH, Düren, Germany)
staining. All products were confirmed by sequencing [5].
Statistics
Statistical analyses were done using Prism 5 (GraphPad
Software, San Diego, CA, USA). For the confluence mea-
surements an unpaired t-test was performed (P < 0.05).
A one-way ANOVA followed by the Newman–Keuls
post-test (P < 0.05) was performed for ROS (DCFH2-DA)
measurements.
Results
We detected L-DOPA in IVF-derived FF by using
ELISA measurements (Fig. 1a; n = 11 preparations).
The levels varied (range 6.8–9.8 ng/ml), but on aver-
age a concentration of 8.2 ng/ml was quantified. L-
DOPA was also detected in serum samples, obtained
from a total of 11 different women (Fig. 1b). The
levels varied and ranged from 7.4 to 40.9 ng/ml, with
an average of 16.7 ng/ml.
Next, the role of L-DOPA was explored in cultured
human GCs. L-DOPA in the medium enhanced the sur-
vival of cultured GCs (P < 0.05). This is concluded from
automated confluence measurements of cultured GCs,
treated with L-DOPA compared to control cells (Fig. 2a).
When DA was used instead of L-DOPA, confluence was
reduced (P < 0.05) indicating reduced cell survival
(Fig. 2b).
Amplex red assays revealed that H2O2 is a specific
product of cultured human GCs under basal conditions.
H2O2 levels increased during a 2 h measurement. This
was seen in several independent measurements (Fig. 3a).
We speculated that the trophic role of L-DOPA may be
related to an interference with H2O2 and or its conse-
quences in GCs. This mode of action of L-DOPA was
identified in further experiments using the ROS indica-
tor DCF and exogenous H2O2. H2O2-scavenging actions
of L-DOPA were observed, which occurred rapidly and
were depending on the concentration of L-DOPA
(Fig. 3b; Additional file 1). Concentration levels as low
as 20 nM were sufficient for a significant effect.
DDC converts L-DOPA to DA and immunohisto-
chemistry showed its presence in the theca cells (TCs)
but not GCs of large human follicles and the cells of the
CL in the human ovary. The pre-adsorption control sup-
ports specificity of the immunohistochemical staining
(Fig. 4a-d). Results of laser microdissection studies of
the cells of the follicular wall followed by RT-PCR
(Fig. 4e-h) also showed the presence of DDC in this tis-
sue. In cultured human GCs, DDC mRNA was not de-
tectable (Fig. 4i). DA was reported previously in FF in
higher concentrations than in serum ([4]), suggesting a
local synthesis.
Discussion
To our knowledge neither presence nor functions of
L-DOPA in the human ovary, in FF and human GCs
Blohberger et al. Journal of Ovarian Research  (2016) 9:62 Page 3 of 7
have been examined. We readily detected L-DOPA in
IVF-derived FF and found that the concentration
range is somewhat lower compared to serum. Serum
values of L-DOPA in women undergoing IVF are not
published to our knowledge, but the reported serum/
plasma levels in humans vary substantially, when de-
termined by HPLC [21]. In comparison, our results
obtained by ELISA measurements indicate somewhat
higher levels than described [22]. This observation
may be conditioned by the IVF treatment, since L-DOPA
may to be linked to gonadotropin levels [23, 24], but also
be due to inter-individual variation due to metabolism and
nutrition. Thus further studies will require extensive re-
cruitment of patients.
L-DOPA has anti-oxidative abilities [12, 13]. The
mechanisms are not fully known, but include a ROS
scavenger action, as well as induction of gene expression.
The nature of L-DOPA to specifically antagonize H2O2
was previously shown [12, 14, 25]. In GCs the rapid on-
set of effects, which were observed in the ROS measure-
ments within minutes (Additional file 1), support the
scavenger abilities of L-DOPA. Other actions of L-
DOPA in GCs remain to be shown.
We found that GCs produce H2O2, but the reasons re-
main to be fully elucidated. Several enzymes, namely ste-
roidogenic enzymes, oxidases (specifically the NOX 4
and 5 enzymes [26]) may be responsible for ROS
generation.
DA, formed by DCC from L-DOPA, is a factor de-
scribed previously in high concentrations in FF and it in-
creases the generation of H2O2 in GCs. This is due to
uptake and cellular metabolism of DA [4]. In GCs this
may lead to oxidative stress and our studies using an au-
tomated evaluation of cell confluence indeed revealed a
deleterious action of DA. In contrast L-DOPA increased
cell confluence. Cell confluence is a measure for cell via-
bility, cell number and/or size and increases seen in the
L-DOPA group can be interpreted as overall trophic ac-
tion [4, 5, 26]. Results of cell counting after exposure to
L-DOPA confirm this assumption (data not shown).
Clearly, a detailed evaluation of the cellular events,
which may also include cell death events, are required to
decipher the actions of L-DOPA.
If transferable to the in vivo situation, DA and L-
DOPA thus may act antagonistically on the ROS envir-
onment of the follicle. The present study also indicates
Fig. 1 L-DOPA levels in follicular fluid and serum. a L-DOPA levels in in vitro fertilization (IVF)-derived follicular fluid samples. Individual values of
11 FF are given, as well as the mean and SD. b Individual values of L-DOPA in sera from 11 patients are given, as well the mean and SD. Note
that the samples shown in a and b do not stem from the same patients
Fig. 2 DA and L-DOPA effects on cultured human GCs. a Treatment with L-DOPA (200 nM) causes a significant increase of confluence in human
GCs after 24 h compared to control group (P < 0.05, t-test). b DA (200 nM) stimulation decreases confluence in human GCs after 24 h compared
to control group (P < 0.05, t-test). All values are shown as well as mean ± S.E.M. of n = 5 independent preparations of cells from two to five
patients each
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Fig. 3 Production of H2O2 and ROS in cultured human GCs. a Measurement of H2O2 using amplex red shows generation of H2O2 occurring over
2 h. Values are shown as mean ± S.E.M of n = 3 experiments. b L-DOPA (200 nM) significantly blocks H2O2 (1 mM) dependent DCF fluorescence inten-
sity (P < 0.05, ANOVA, Newman-Keuls). Values are shown as mean ± S.E.M. of n = 3 independent preparations of cells from two to five patients each.
Note that shown values are resulting from endpoint measurements after 2 h
Fig. 4 DDC in human ovarian tissue. a In human ovarian tissue TCs are positive for DDC in an immunohistochemical staining. b The pre-adsorption
control is devoid of staining. c Cells of the human corpus luteum are positive for DDC using immunohistochemistry. d Pre-adsorption abolished
staining of the corpus luteum. e–g Micrographs of human ovarian tissue before (e), during (f) and after (g) LMD. TCs and GCs of the follicle wall were
excised. After RNA extraction a RT-PCR was performed. Bars indicate 50 μm (a and b) and 100 μm (c–g). h RT-PCR and sequencing showed, that DDC
mRNA is present in samples of human TCs/GCs. All controls (input of H2O instead of cDNA and RNA instead of cDNA) were negative. i DDC mRNA is
absent in cultured human GCs (hGC; pool of seven preparations). Human liver cDNA was used as positive control. Controls (input of H2O instead of
cDNA) were negative
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that L-DOPA levels in FF are somewhat lower than the
ones in serum, at least in samples available to us. How-
ever, FF and serum samples do not stem from the same
women, hence this point must be evaluated further.
The samples from human CLs available to us were
positive for DDC protein. They likely stem from the mid
phase of the life span of the CL. Unfortunately the ex-
pression of DDC in other phases of the CL (formation,
regression) could not be studied due to a lack of sam-
ples. We did not detect DDC in IVF-derived cultured
GCs. They were cultured under basal conditions for a
few days and may represent cells comparable to the
young, forming CL. This may in part explain the dis-
crepancy but, clearly, a more detailed study on DDC-
expression during the life span of the CL will be
required.
Expression of DDC in TCs and in the CL imply that
DA can be generated in the ovary from its immediate
precursor, rather than from L-tyrosine, since TH, the
rate limiting enzyme, was reported in neuronal elements
but not in TCs and GCs of the human ovary [7]. In
brain expression of different catecholamine-synthesizing
enzymes in different neurons were reported [27], imply-
ing that synthesis of catecholamines not necessarily de-
pends on de novo synthesis from L-tyrosine in all cells.
With regard to the ovarian pathophysiology, DCC ex-
pression in TCs may imply that their number and the
presence of a CL could be correlated with higher DA
levels within the ovary. The relevance for PCOS, in
which hyperthecosis is reported, remains to be shown.
However we have previously shown higher DA in FF of
PCOS women undergoing IVF [4], a result that could be
related to more TCs (hyperthecosis) expressing DDC.
In summary, L-DOPA could be an antioxidant factor
of relevance for the human ovary. This conclusion from
our studies raises the question whether an enhanced ex-
ogenous supply of L-DOPA may be a novel therapeutic
approach to treat ovarian conditions related to oxidative
stress. Furthermore, to our knowledge positive actions of
systemic L-DOPA in mice were reported. They include a
small increase in fertility, namely increased litter size
[28]. Reports in human are however to our knowledge
almost missing, a fact related to the onset of Parkinson's
disease after childbearing years [29]. Only one brief
study stemming from 1980 reported that L-DOPA posi-
tively affects female fertility [30].
Conclusions
Taken together our results indicate that L-DOPA is an
antioxidant factor in the human ovarian system. In con-
trast to DA it shows positive effects on granulosa cells.
Since L-DOPA is used in therapy of Parkinson disease, it
may be relevant for treatment of ovarian diseases as
well.
Additional file
Additional file 1: ROS generation in cultured human GCs. A L-DOPA
(2 nM, 20 nM) reduces H2O2-dependent (1 mM) DCF fluorescence
intensity during 2 h of stimulation. B Endpoint measurements of cells
treated witch L-DOPA (2 nM) after 2 h show a slightly reduced H2O2-
dependent ROS signal. A L-DOPA concentration of 20 nM leads to a
significantly decreased ROS generation (P < 0.05, ANOVA, Newman-
Keuls). All values are shown as mean ± S.E.M. of n = 4 independent
preparations of cells from two to five patients each. Different letters
indicate statistically significant differences between the treatment
groups. (DOCX 192 kb)
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